Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.60 |
| ▸ | TYR | P14679 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30561814 | 1.00 | PTPN1 (0.60) | PTPN1TYRCYP19A1ALOX12ALOX15 | |
| (3R)-Sativanone SCHEMBL30635254 | 0.90 | PTPN1 (0.61) | PTPN1TYRCYP19A1ALOX12ALOX15 | |
| (3R)-Sativanone SCHEMBL29576626 | 0.90 | PTPN1 (0.61) | PTPN1TYRCYP19A1ALOX12ALOX15 | |
| SCHEMBL31290567 | 0.88 | PTPN1 (0.56) | PTPN1TYRCYP19A1ALOX12ALOX15 | |
| SCHEMBL31290566 | 0.88 | PTPN1 (0.56) | PTPN1TYRCYP19A1ALOX12ALOX15 | |
| SCHEMBL21168204 | 0.85 | PTPN1 (0.72) | PTPN1TYRCYP19A1ALOX12ALOX15 | |
| SCHEMBL2069507 | 0.85 | ALOX12 (0.74) | PTPN1CYP19A1ALOX12ALOX15CYP3A4 | |
| SCHEMBL29559241 | 0.85 | ALOX12 (0.74) | PTPN1CYP19A1ALOX12ALOX15CYP3A4 | |
| SCHEMBL29688602 | 0.84 | PTPN1 (0.55) | PTPN1TYRCYP19A1ALOX12ALOX15 | |
| (3R)-3'-O-Methylviolanone SCHEMBL31237773 | 0.81 | PTPN1 (0.60) | PTPN1CYP19A1ALOX12ALOX15CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115109809-B | Midecarin is a biosynthesis method of (2) | 南京中医药大学 | 2025-03-04 | — | — | CN | claimed |
| US-20250051551-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2025-02-13 | — | — | US | claimed |
| CN-115109809-A | Biosynthesis method of santalin | 南京中医药大学 | 2022-09-27 | — | — | CN | claimed |
| US-20020177527-A1 | Methods for the identification of inhibitors of 2'-hydroxyisoflavone reductase expression or activity in plants | ICORIA, INC. | 2002-11-28 | — | — | US | claimed |
| WO-2002092776-A2 | METHODS FOR THE INDENTIFICATION OF INHIBITORS OF 2-HYDROXYISOFLAVONE REDUCTASE EXPRESSION OR ACTIVITY IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2002-11-21 | — | — | WO | claimed |
| CN-122055354-A | Lipid compounds and related compositions and uses | 波西达治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | THE BROAD INSTITUTE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250376656-A1 | MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-12-11 | — | — | US | disclosed |
| WO-2025049925-A2 | LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES | POSEIDA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-115109809-B | Midecarin is a biosynthesis method of (2) | 南京中医药大学 | 2025-03-04 | — | — | CN | disclosed |
| US-20250051551-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2025-02-13 | — | — | US | disclosed |
| US-12163004-B2 | Polymer composites | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-12-10 | — | — | US | disclosed |
| US-20050241014-A1 | Nutritionally enhanced plants | UNILEVER PATENT HOLDINGS B.V. (NL) | 2005-10-27 | — | — | US | disclosed |
| CN-1650017-A | Production of dadzein in transgenic plants | UNILEVER NV (NL) | 2005-08-03 | — | — | CN | disclosed |
| WO-2005047498-A1 | OPTIMISED MICRO-ORGANISM STRAINS FOR NADPH-CONSUMING BIOSYNTHETIC PATHWAYS | METABOLIC EXPLORER (FR) | 2005-05-26 | — | — | WO | disclosed |
| US-20020177527-A1 | Methods for the identification of inhibitors of 2'-hydroxyisoflavone reductase expression or activity in plants | ICORIA, INC. | 2002-11-28 | — | — | US | disclosed |
| WO-2002092776-A2 | METHODS FOR THE INDENTIFICATION OF INHIBITORS OF 2-HYDROXYISOFLAVONE REDUCTASE EXPRESSION OR ACTIVITY IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2002-11-21 | — | — | WO | disclosed |
| US-5750399-A | CONTROL TRANSCRIPTION IN PLANTS | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 1998-05-12 | — | — | US | disclosed |
| EP-0792356-A1 | ISOFLAVONE REDUCTASE PROMOTER | The Samuel Roberts Noble Foundation, Inc. (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1996015239-A2 | ISOFLAVONE REDUCTASE PROMOTER | THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | STUB1, SAMM50, CD14 | PTPN1 85/4885TYR 619/4885CYP19A1 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.